Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Cancer Prevention Clear all
Completed Not applicable Interventional

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

NCT00002043
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Dapsone
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities

NCT00130143
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Ethyol (Amifostine)
Drug
Lead sponsor
The Dale & Frances Hughes Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Stroudsburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2005 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?

NCT00420160
View directory record Official record
Conditions
Lung Cancer, Heart Disease, COPD
Interventions
Smoking cessation treatment plus moderate intensity exercise, Smoking cessation treatment plus health education
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

NCT05672355
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions
Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 5:26 PM EDT
Not yet recruiting Phase 2 Interventional

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Iloprost in Preventing Lung Cancer in Former Smokers

NCT02237183
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care

NCT01346839
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Prostate Cancer
Interventions
Contact Intervention
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
1,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 28, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

NCT05438498
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Evusheld (tixagevimab+cilgavimab) IM or IV
Drug
Lead sponsor
MediMergent, LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
40
States / cities
Corona, California • Fountain Valley, California • Oxnard, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 28, 2026, 5:26 PM EDT
Recruiting Phase 4 Interventional

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

NCT07357597
View directory record Official record
Conditions
Stomatitis
Interventions
Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
39
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Milatuzumab for Graft Versus Host Disease

NCT01663766
View directory record Official record
Conditions
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Interventions
milatuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586
View directory record Official record
Conditions
Drug Toxicity, Lung Cancer
Interventions
13-cis retinoic acid, Tocopherol
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
4
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 28, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

NCT04381988
View directory record Official record
Conditions
COVID-19, Cancer
Interventions
Hydroxychloroquine, Placebo, Radiation therapy
Drug · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 28, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

NCT05120869
View directory record Official record
Conditions
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Interventions
Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Cruces, New Mexico • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer

NCT00012103
View directory record Official record
Conditions
Lung Cancer
Interventions
bronchoalveolar lavage, screening questionnaire administration, sputum cytology, bronchoscopic and lung imaging studies, bronchoscopy, computed tomography, study of high risk factors
Other · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 28, 2026, 5:26 PM EDT
Completed No phase listed Observational

Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy

NCT00310115
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
Smoking Prevention Usual Care, Counseling Intervention
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 28, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Results available

Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection

NCT00300495
View directory record Official record
Conditions
Atrial Fibrillation, Lung Cancer
Interventions
Amiodarone, Control arm, standard care
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking

NCT00033592
View directory record Official record
Conditions
Lung Cancer
Interventions
placebo, bupropion hydrochloride, nicotine
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
24
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Capitalizing on a Teachable Moment to Promote Smoking Cessation

NCT02276664
View directory record Official record
Conditions
Smoking Cessation
Interventions
Self-Help (SHI), Usual Care (UC)
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab for Prevention of Chronic GVHD

NCT00379587
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Rituximab, 375 mg/m2 RRituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free

NCT05362318
View directory record Official record
Conditions
Smoking, Tobacco Use, Lung Cancer
Interventions
Nicotine patch and lozenges, Telephone counseling sessions, Access to a web-based video, Florida Tobacco Quitline
Drug · Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding

NCT05123118
View directory record Official record
Conditions
Smoking, Cigarette, Breastfeeding
Interventions
Integrated intervention of smoking cessation and breastfeeding, Attention placebo control
Behavioral
Lead sponsor
Xiaozhong Wen
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 28, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Oltipraz in the Prevention of Lung Cancer in People Who Smoke

NCT00006457
View directory record Official record
Conditions
Lung Cancer
Interventions
oltipraz
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 28, 2026, 5:26 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Prevention of Post-operative Pneumonia (POPP)

NCT01446874
View directory record Official record
Conditions
Post-operative Pneumonia, Lung Cancer, Esophageal Cancer
Interventions
0.12% chlorhexidine solution
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 28, 2026, 5:26 PM EDT